Americas The Head of Viatris Latin America, Patrick Doyle, spoke to PharmaBoardroom about setting up the two-year old company’s Latam affiliate during the pandemic, the decision to focus on specific therapeutic areas—cardiovascular disease, central nervous system (CNS) disorders, and pain—in LatAm and Viatris’ aim to partner with local stakeholders and go…
Algeria Long considered maladies of affluent urban populations in mature Western economies, non communicable diseases (NCDs)– such as diabetes, cancer, chronic respiratory and cardiovascular diseases – have been spreading silently and unchecked throughout the African continent to the point where they are now reaching epidemic proportions and becoming a major determinant…
Algeria Algeria’s key macroeconomic and healthcare indicators. Cardiovascular disease prevalence in North Africa. Diabetes prevalence in North Africa. The rate of change in the number of years of healthy life lost to obesity in Africa. Click here to download the latest roundtable discussion on Algerian healthcare.
Pharma Elena Tremoli, Scientific Director at Centro Cardiologico Monzino, explains the importance of both applied and cardiovascular research in Italy, and how prevention in this area will be key in the future. Centro Cardiologico Monzino is the only institute of excellence in Europe exclusively devoted to cardiovascular diseases. Can you describe…
Pharma Albert Denoon (AB) and Jeff Hampton (JH) illustrate how the Crossroads and Campbell Institutes, two non-profit organizations funded by Baroque Medical, are well positioned to address South Africa’s current gaps in medical training. They also depict the key success factors that have allowed the company to become the leading distributor…
Pharma Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer specifically to engage the government in the development of a more sustainable healthcare system. To start off, we are approaching…
Pharma Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager Jasper van Grunsven explains the challenges of preparing for the upcoming year in the midst of structural changes to the…
pharma The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie, while also highlighting branded generics as a key growth driver and how the company plans on expanding its capabilities in…
pharma Ileana Quiñones, president and general manager of iPR-AstraZeneca, discusses the clear strategy of the affiliate in being a leading manufacturer in Puerto Rico and the steps necessary to ensure their place in the country and within the AstraZeneca organization. Where is AstraZeneca focused today and how does the Puerto Rican…
pharma The general manager of Ali Raif, Muzaffer Bal illustrates the various success factors that allowed the company to secure market leading positions within Turkey and across Europe, while also highlighting how the company has adapted its portfolio to shifting market dynamics. Muzaffer, as an introduction for our readers, please provide…
AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…
UCB UCB’s managing director for Turkey and the MEA region discusses UCB’s leading patient centricity, how UCB is addressing gaps in the Turkish healthcare system surrounding epileptic patients, and the company’s plan for regional expansion through partnerships. Given your patient centricity and UCB’s unique perspective, how would you assess the sectors approach…
See our Cookie Privacy Policy Here